Treace Medical Concepts (NASDAQ: TMCI) Exceeds Q3 2026 Estimates Despite Continued Unprofitability
Treace Medical Concepts (NASDAQ: TMCI) reported an adjusted Q3 2026 loss of $0.19 per share, outperforming the estimated loss of $0.25 per share. Revenue reached $48.25 million, surpassing the $47.8 million estimate, though it marked a decrease from the prior year's $50.21 million. Despite…